Poppins Clinical 成为法国首个在PECAN计划下报销的治疗性应用

做的是什么生意

Bmotion Technologies makes Poppins Clinical, a prescription video-game digital medical device that trains reading in children aged 7-11 with specific learning disorders, designed as home-based therapy complementing speech therapy.

启动资金：About €20M raised across three rounds: €4M in 2021, €8M in 2023 (Eurazeo and others), and €5M in April 2025 led by Racine2 (MGEN's impact fund, managed by Serena and makesense).

起因

François Vonthron and Antoine Yuen founded Poppins in 2018 to attack a structural shortage: France has roughly 1.3 million dyslexic children but only about 25,000 speech therapists, leaving 12-24 month waits for assessment. The app trains reading through 31 game-based rhythm and written-language exercises. France then created the channel Poppins needed: decree 2023-232 of 30 March 2023 introduced PECAN, an early-access reimbursement scheme for innovative digital medical devices (therapeutic devices and remote-monitoring devices) launched in April 2023.

经过

Poppins raised €4M in 2021, €8M in 2023, and €5M in April 2025 (Racine2/MGEN-led, with Bpifrance's Patient Autonome fund, Eurazeo, Kurma Partners, BNP Paribas Développement and Verve Ventures), bringing total funding to about €20M. It used the money to run the clinical work and regulatory path to become a reimbursed digital medical device. For two years every PECAN order went to remote-monitoring devices; Poppins Clinical kept pushing as the first therapeutic candidate.

结果

The Ministry of Health's arrêté of 17 July 2026, published in the Journal Officiel on 21 July 2026, made Poppins Clinical the first therapeutic digital medical device covered under PECAN: an initial package for up to three months plus monthly renewals, capped at €780 per patient per year. A rectifying arrêté of 29 July 2026 followed, explicitly allowing speech therapists to prescribe and renew, after the FNO protested that the first version excluded them.

可借鉴之处

对于数字治疗，报销才是真正的产品：尽早匹配证据要求，让初创企业在专业团体甚至对抗规则之前就定义类别。